Zentalis Pharmaceuticals, Inc. (ZNTL) Misses Q2 EPS by 82c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Join SI Premium – FREE
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) reported Q2 EPS of ($1.85), $0.82 worse than the analyst estimate of ($1.03).
For earnings history and earnings-related data on Zentalis Pharmaceuticals, Inc. (ZNTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
- Rambus (RMBS) Tops Q3 EPS by 5c, Offers Guidance
- Dorman Products (DORM) Tops Q3 EPS by 8c, Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
